Cytospire Therapeutics
PrivateLast Round
Series A
May 5, 2026
Total Funding Raised
$83M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Cytospire Therapeutics operates in Healthcare & Life Sciences and is based in London. Its latest recorded funding round was a Series A round in May 2026.
Cytospire Therapeutics is a biotechnology company developing a portfolio of differentiated multispecific engager antibodies to enhance and direct the activity of innate and adaptive effector immune cells for the treatment of cancer.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Revenue Share
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Cytospire Therapeutics Comparables
Compare Cytospire Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Janux Therapeutics | 77% | |
| Ipsen | 76% | |
| Lava Therapeutics | 75% |
For institutional investors. Book with your work email.
Cytospire Therapeutics Funding Rounds
Historical fundraising activity
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Cytospire Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Servier Ventures | Series A |
| Medical Incubator Japan | Series A |
| British Business Bank | Series A |
| 4BIO Capital | Seed, Series A |
| Abingworth | Series A, Seed |
| Pathway Bioventures | Series A |
| LifeArc Ventures | Series A, Seed |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 1, 2026
Grew 47% QoQ, from 19 to 28 employees.
- May 27, 2026
Grew 17% QoQ, from 18 to 21 employees.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- hiresSep 9, 2026
Cytospire Therapeutics Limited appoints Sumeet Ambarkhane as Chief Medical Officer to lead clinical development and regulatory strategy for its multispecific immune-cell engager programmes in the United Kingdom on Sep 9th '26.
- is_developingSep 8, 2026
Cytospire Therapeutics Limited is developing an innovative portfolio of differentiated multispecific engager antibodies to enhance and direct innate and adaptive effector immune cells in the United Kingdom as of Sep 8th '26.
- hiresSep 8, 2026
Cytospire Therapeutics Limited appoints Sumeet Ambarkhane, M.D., as Chief Medical Officer to support CYT X300's clinical development in United Kingdom on Sep 8th '26.
For institutional investors. Book with your work email.
Cytospire Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Cytospire Therapeutics's valuation, stock price, and market status.
Is Cytospire Therapeutics a public or private company?
Cytospire Therapeutics is a private company.
What is the current stock price of Cytospire Therapeutics?
Cytospire Therapeutics is a private company, so its shares have no public market price. Caplight tracks Cytospire Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Cytospire Therapeutics worth (valuation)?
Valuation information for Cytospire Therapeutics is not publicly available.
Can I buy Cytospire Therapeutics stock?
Cytospire Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Cytospire Therapeutics's last funding round?
Cytospire Therapeutics's most recent funding round was Series A on May 5, 2026.
Who are the main investors in Cytospire Therapeutics?
Key investors in Cytospire Therapeutics include 4BIO Capital, Abingworth.
Will Cytospire Therapeutics IPO soon?
No public IPO plans have been announced for Cytospire Therapeutics.
How can I track Cytospire Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Cytospire Therapeutics's shares on secondary markets.